Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Jun
21
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Overall Survival With EBRT in Hepatocellular Carcinoma
HCC TACE Plus STRIDE With or Without Lenvatinib
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo